Table Of Content

AUTHOR INDEX VOLUME 5, 1991 Note: In brackets, abs indicates abstract, br indicates book review, and let indicates letter to the editor. Antonello, J.M., 337, 353 Faber, K.A., 363 Laschinski, G., 57 266, [abs] 267, [abs] 268, Asada, S., [abs] 265, [abs] 265 Fantel, A.G., 259 Lau, C.-F., 405 [abs] 270, 417 Ataya, K.M., 73 Finnell, R.H., 281, 301 Laumon, B., 83 Piersma, A.H., [abs] 266, [abs] Attenon, J., [abs] 267, 417 Fisher, H.L., 255 Lee, Q.P., 259, 473 267, [abs] 270, 417 Fournex, R., [abs] 269 Lemasters, G.K., 31 Plessinger, M.A., 99 Baden, J.M., [abs] 268 Fujimoto, M., [abs] 265 Lendon, R.G., 497 Plowchalk, D.R., 379 Baer, R.K., 115 Fujinaga, M., [abs] 268 Leonhardt, D.E., 157 Pradat, E., 83 Barr, R.D., 385, 481 Fukiishi, Y., [abs] 265 Levy, M., 79 Prahalada, S., 337, 347, 353 Basham, K.B., 127, 133, 363 Li, K., [abs] 268 Pydyn, E.F., 73 Bauserman, S., 517 Gadisseux, J.F., [abs] 266 Lindh, U., 53 Bechter, R., [abs] 267 Garrettson, L.K., 397 Lione, A., [br] 85, [br] 273 Rao, K.S., 175 Benkendorf, J.L., 87 George, E.L., 487 Logsdon, T., 255 Rao, M.V., 505 Bernfield, M.R., [abs] 267 Goethals, F., [abs] 268 Lorenzon, G., [abs] 269 Read, E.J., 487 Berthet, P., 417 Gofflot, F., [abs] 266, [abs] 268 Reece, $.G., 133 Blazak, W.F., 175 Gold, W.R., 517 MacDonald, J.S., 337, 353 Repetto, M., [abs] 269 Bodo, L., 481 Govers, M.J.A.P., [abs] 267, 417 Martinez, E.M., 139 Robert, E., 83 Bradshaw, W.S., 157 Gray, L.E., Jr., 39 Mattison, D.R., 175, 379 Robertson, R.T., 337, 347, 353 Brook, FA, [abs] 265 Gressens, P., [abs] 266 McCants, C.E., 127 Rorem, M., 397 Brown, N.A., 3, 245 Gubbels, J.L., 517 McCarthy, A., 245 Rourke, A.W., 437 Gupta, S.K., 443 McLachlan, J.A., 149 Roux, C., [abs] 269 Chakinala, M.M., 133 McMahon, A., 385 Chandra, S.V., 211, 443 Hall, L.L., 255 Meier, M., [abs] 269 Samson, I., 397 Chinoy, N.J., 505 Hamers, A.E.P., [abs] 266 Miller, R.N., 133 Santti, R., 149 Citadelle, D., [abs] 269 Hanson, J.W., 175 Minsker, D.H., 337 Savoy—Moore, R.T., 371 Clark, R.L., 337 Hansen, K., 31 Moller—Madsen, B., 205 Saxena, D.K., 211, 443 Clark, S., 31 Harris, C., 259 Morris, I1.D., 497 Scanlon, J.W., 89 Clarke, D.O., 245 Hasegawa, Y., [abs] 265 Murthy, R.C., 211, 443 Schmid, B.P., [abs] 265, [abs] Cockroft, D.L., 223 Hertzberg, V., 31 267, 417 Coleman, L.W., 157 Hill, K., 397 Nahas, G.G., 389 Schomberg, D.W., Jr., 133 Colie, C.F., [br] 525 Hughes, C.L., Jr., 127, 133, 175, Namkung, M.J., 259, 473 Schrader, $.M., 115 Copeland, F., 255 363, 462 Nanbo, T., 411 Scialli, A.R., 1, [br] 85, [br] 163, Copius Peereboom-Stegeman, Narayana, M.V., 505 [br] 164, 279, [br] 391, 395, JHJ, {abs} 270 Ionov, I.D., [let] 526 Nau, H., 465, [abs] 269 {br} 459, [br] 521 Copp, A.J., [abs] 265, [abs] 267 Neelakanta, E., 505 Sharav, T., 397 Cordier, A., [abs] 268 Jackson, F.L., [let] 522 Nemoto, A.S., [abs] 265 Sheriff, D.S., 513 Crowther, C., [abs] 268 Jansen, E.H.J.M., [abs] 266 Newbold, R.R., 149 Sina, J.L., 347, 353 Cukierski, M.A., 337, 347, 353 Jarrell, J.F., 385, 481 Nilsson, B.O., 53 Singh, C., 211 Joosten, H.F.P., [abs] 271 Singh, U.S., 211 Danscher, G., 205 Jost, L.K., 115 O'Brien, J., 463 Sipes, 1.G., 379 Dansky, L.V., 281, 301 Juchau, M.R., 259, 473 O'Connell, G.J., 481 Slott, V.L., 449 Davis, D.L., [br] 274 Obe, G., 405 Smith, B.J., 379 Deboyser, D., [abs] 268 Kaldas, R.S., 127 Oglesby, L.A., 255 Smith, M.K., 487 Delhaise, F., [abs] 270, 417 Kaneko, S., 179 Olive, D.L., 175 Spezia, F., [abs] 269 Denis, S., [abs] 268 Kavlock, R.J., 255 Orr, E.L., [let] 522 Spielmann, H., 57, 405 Dolgin, J.E., 397 Kesby, G.J., [abs] 266 Osumi-Yamashita, N., [abs] 265 Stadler, J., [abs] 267, [abs] 270, Dupuis, R., [abs] 269 Kihlstrém, I., [abs] 269 {abs} 270, 417 Killinger, J.M., 175 Paksy, K., 199 Stark, K.L., 259 Ebron—McCoy, M., 255 King, A., 397 Palminger, I., [abs] 269 Stober, J.A., 487 Ellington, S.K.L., 229 Klinefelter, G.R., 39 Pastuszak, A., 397, 79 Suarez, J.D., 39, 449 Ernst, E., 205 Klug, S., 237, [abs] 266 Pease, W., 169, [let] 525 Sullivan, F.M., 393 Eroschenko, V.P., 427, 437 Kochhar, D.M., 175 Perreault, $.D., 449 Sunde, T., 53 Estibeiro, J.P., [abs] 265 Koelman—Klaus, E.J.S., [abs] 271 Peters, P.W.J., [abs] 266, [abs] Swartz, W.J., 139 Eto, K., [abs] 265, [abs] 265 Kolf-—Clauw, M., [abs] 268 267, [abs] 270, 417 Evenson, D.P., 115 Koren, G., 79, 397 Piasek, M., 45 Teaff, N.L., 371 Evrard, P., [abs] 266 Kostial, K., 45 Picard J.J., 221, [abs] 267, [abs] Terlouw, G.D.C., [abs] 267 xl Thomson, S.D., 497 [abs] 267, [abs] 267, [abs] 268, Vogel, R., 57, 405 Woods, J.R., Jr., 99 Toth, G.P., 487 [abs] 270, 417 Wordinger, R.J., [let] 526 Turner, T.W., 115 van Straaten, H.W.M., [abs] 267 Walsh, D., [abs] 268 Working, P.K., 175 Vannier, B., [abs] 269 Washburn, L.J., 437 Uphouse, L., 65 Varga, B., 199 Wegner, C., 465 Yamashita, N., [abs] 265 Verhoef, A., [abs] 266, [abs] 267, Weisinger, A.S., 127 Yang, H.-Y. L., 473, 259 van Aerts, L.A.G.J.M., [abs] 270 [abs] 270, 417 Wide, M., 53 Yih, T.D., [abs] 271 van den Dobbelsteen, D.J., [abs] Verseil, C., [abs] 267, [abs] 270, Williams, J., 65 YoungLai, E.V., 385, 481 271 [abs] 270, 417 Wise, L.D., 337, 353 Van Maele—Fabry G., [abs] 266, Zenick, H., 31 KEY WORD INDEX VOLUME 5, 1991 Note: In brackets, abs indicates abstract, br indicates book review, and let indicates letter to the editor. ablation, seminal vescicle/coagulating carboxylic acids/valproic acid, transfer, WEC, 473 gland, rats, 347 activity, 269 cytotoxicity test, embryonal stem cells, 57 acetaldehyde, preimplantation mouse em- Cardiac Problems, Pregnancy, [br] 521 bryos, 405 cardiovascular effects, cocaine, pregnancy, DDT, o,p’-, pituitary responsiveness to acetylaminofluorene, 2-, WEC, 259 99 GnRH, rats, 363 acridine orange, human sperm, 115 CASA, rat, 449 DES acyclovir, diastematomyelia, fetal, 517 categorization of drugs, pregnancy, FDA, estrogenized male rats, 149 AEDs, reproductive consequences, 179 [let] 393 pituitary responsiveness to GnRH, rats, alcohol dehydrogenase, preimplantation CellSoft, rat sperm motility analysis, 387 363 mouse embryos, 405 cerebral vascularization, rat embryo cul- designer drugs, cocaine, marijuana, [br] amantadine hydrochloride, fetal outcome, ture, 265 273 65 chemicals, classification, WEC, 267 developing fetus, mean residence time, androgen metabolism, 139 chlorinated pesticides, estrous cycle, fe- 411 androgenization, xenobiotic estrogens, 363 male rat, 65 developmental animal models, anticonvulsant drugs, 281 cholesterol, WEC, 245 delay, anticonvulsants, human, 301 antiepileptic drugs, reproductive conse- chromium, hexavalent, rat testis, 443 toxicity, phenols, 255 quences, 179 chromosome aberrations, ethanol, 405 Toxicology, In Vitro Methods, [br] 85 anticonvulsants classification of drugs, pregnancy, FDA, variations, WEC, 270 animal models, 279 [let] 393 dialyzed serum, 223 human studies, 301 clearance, rat fetus, 411 diastematomyelia, fetal, acyclovir expo- assay, sperm chromatin structure, 115 cleavage, cyclophosphamide, 73 sure, 517 autometallography, 205 coagulating gland/seminal vesicle ablation, diethylstilbestrol, androgen, 149 awards, graduate/postdoctoral student, rats, 347 distribution, steady-state volume of, 411 531 cocaine diurnal variation, folate, 465 Ayurvedic Medicinal Plants, [br] 85 cardiovascular effects, pregnancy, 99 DNA denaturation, 115 marijuana, designer drugs, [br] 273 Drug Safety in Pregnancy and Lactation, neuroteratology, 89 [br] 459 benzo(a)pyrene, ovarian effects, 379 computer-assisted sperm analysis, rat, 449 biotransformation, 473 convulsions, anticonvulsants, 279 eating behavior, chlorinated pesticides, 65 birth defects, anticonvulsant drugs copulatory plug deficits EDS, testis, 39 animal models, 281 finasteride, 353 embryo Chemically Induced, [br] 459 seminal vesicle ablation, 347 culture, morphogenesis, 229 human studies, 301 culture media rat, EGdiME, 157 Teratogens, Chemicals Which Cause, postimplantation embryos, 223, 417 valproate exposure, 245 [br] 459 cyclic nucleotides, 473 Embryology, Langman’s Medical, [br] 391 buffers, HCl, NaOH, effects, WEC, 270 cyclophosphamide embryonic bioactivation, 270 development, ethanol, 405 cadmium, LHRH-induced LH release, 199 oocyte, 65 dosimetry, WEC, 255 California, proposition 65, 169, 175 [let] ovarian toxicity, 379 stem cells, 57 525 short-term toxicity, rat, 481 embryotoxicity, P450-catalyzed dealkyla- carbohydrate, WEC, 229 cytochrome P450 tion, 473 carbon monoxide, pregnancy, fetus, 397 prodysmorphogens, 259 endometrial histamine, 526 xi Endowment Fund, Susan Fiery Hughes, GnRH-induced LH secretion, genistein, lipid 277, 462, 530 127 peroxide levels, vanadium, 513 endpoints, WEC, 237 gonadotrophins, neonatal rats, dimethane- synthesis, WEC, in vivo & in vitro, 245 ENTIS, OTIS, teratology information net- sulphonate, 497 lordosis, chlorinated pesticides, 65 works, 395 gonadotropin-releasing hormone, 133 luteinizing hormone epilepsy granulosa-luteal cells, vinblastine, in vitro, cadmium, 199 anticonvulsant drugs 371 ovariectomized rat, 127, 133 animal studies, 281 growth releasing hormone, cadmium, 199 human studies, 301 retardation, anticonvulsants, human, 301 drug therapy, effects, 179 neonatal rats, dimethanesulphonate, 497 male estradiol WEC, 229 genital tract, 149 chlorinated pesticides, female rat, 65 reproductive physiology, 449 genistein, 127, 133 hazard identification, marijuana, cocaine, designer drugs, [br] methoxychlor, 427, 437 proposition 65, 273 estrogenization, neonatal, 149 California, 169, 175, [let] 525 Maternal—Fetal Toxicology, A Clinicians’ estrous cycle, chlorinated pesticides, 65 hCG, vinblastine, 371 Guide, [br] 164 estrus, persistent, methoxychlor, 139 HCl, NaOH, buffers, effects, WEC, 270 mean residence time, rat fetus, 411 ethane dimethanesulphate heparin plasma, WEC, 266 Mendelian Inheritance in Man, [br] 391 sperm motion, method of collection, 39 hepatocytes, embryos, medium, sequential mercury, rat testis, 205 testicular effects, 497 culture, 268 metabolic activity, yolk sac tissue, 267 ethanol, preimplantation mouse embryos, histamine, endometrial, 526 metabolism, WEC, 229 405 histology methoxychlor ethylene glycol dimethyl! ether, perinatal methoxychlor, 437 adult female mouse, 139 rat, 157 WEC, 269 protein secretions, mouse uterus, 437 European Network of Teratogen Informa- HPLC method, folinic acid, 465 young mice, vagina/uterus, 427 tion Services, 395 Hughes, Susan Fiery, Endowment Fund, Micromass Teratogenicity Test, validation, evaluation, interlaboratory, culture media, 277, 462, 530 271 417 morphologic features, quantitative evalua- Expert Witnessing, Effective, [br] 521 Illicit Drugs, Physiopathology, Sympo- tion, WEC, 270 explanting early postimplantation embryos, sium, 389 morphology, valproate, 245 268 ILSI Committee, Proposition 65, Califor- motion analysis, rat sperm, 449 nia, 525 MTT assay, 57 FDA categorization of drugs, pregnancy, implantation [let] 393 endometrial histamine, 526 NaOH, HCl, buffers, effects, WEC, 270 fecundity experimentally delayed, lead, 53 neonatal rats, ethane dimeth Iphonate, cyclophosphamide, female rat, 481 In Vitro 497 radiation, toxicity, 385 Culture of Postimplantation Rodent Em- networks, teratology information, 395 fertility bryos, proceedings, 221 neural cells, influence of culture, mouse assessment, 353 fertilization, cyclophosphamide, 65 embryos, 266 impairment, rat, sodium fluoride, 505 Methods in Developmental Toxicology, neural plate, regulation, development, 268 finasteride, rat, 337 [br] 85 neural tube sewer wastes, 31 in vivo verfication, WEC, 237 closure delay, quantification, 267 fetal outcome, amantadine hydrochloride, Inheritance, Mendelian, Man, [br] 391 defect, ovulation induction, 83 65 interlaboratory validation, screening, 267 neuroteratology, cocaine, 89 finasteride International Life Sciences Institute—Nutri- neurulation, maternal serum protein, 265 copulatory plug formation, 353 tion Foundation, [let] 521 nutrient requirements, WEC, 223 fertility, male rats, 337 intrauterine insemination, 347 flow cytometry, human semen, 115 iron-deficiency, lead, rats, 211 obstetrics, amantadine, 65 folate, diurnal variation, valproic acid, 465 kidney, fetal, lead, 211 occupational exposures, SFRs, 31 folinic acid, valproic acid, 465 Lactation, Drugs in Pregnancy and, [br] Organization of Teratogen Information Ser- follicle 459 vices, 395 loss, mouse, 379 Langman’s Medical Embryology, [br] 391 OTIS, ENTIS, teratology information net- female rat, cyclophosphamide, 481 lead works, 395, 463 nitrate effects, WEC development, 269 ovarian genistein blastocyst, mouse, 53 failure, cyclophosphamide, 65 subacute administration, 133 fetal kidney, iron-deficient rats, 211 toxicity, random/serial sections, 379 GnRH-induced LH secretion, 127 oral, reversibility, female rats, 45 ovariectomized genital tract, male, 149 Leydig cells mice, methoxychlor, 437 gestation, amantadine, hydrochloride, 65 mercury, rat testis, 205 rat glutathione levels, vanadium, 513 ethane dimethanesulphonate, 497 estrogens, naturally occurring, 133 GnRH, DES, o,p'-DDT, 363 LH, xenobiotic estrogens, 363 luteinizing hormone, 127 xIll ovary reproductive toxicity, finasteride, male effects, ethane dimethanesulphonate, 497 female rat, cyclophosphamide, 481 rats, 337 /liver effects, vanadium, 513 methoxychlor, 139 resorufin ethers, 473 testis ovulation retardation, WEC, 237 ethane dimethanesulphonate, 39 cadmium, 199 retinoic acid, 13-cis, all-trans, WEC 266 neonatal rats, dimethanesulphonate, 497 induction, neural tube defects, 83 testosterone, neonatal rats, dimethane- SCSA, 115 sulphonate, 497 pesticide, protein secretions, mouse uterus, section counting, random vs serial, 379 thalidomide, S9-mix, various species, 269 437 semen quality, human, 115 Therapeutics, Pharmacologic Basis, Good- pharmacokinetics seminal vescicle/coagulating gland abla- man & Gilman's, [br) 391 rat fetus, 411 tion, rats, 347 Toxicology, Fifth International Congress WEC, 237 Sertoli cells, mercury, 205 of, [br] 163 phenols, developmental toxicity assays, sexual 255 behavior, female rat, chlorinated pesti- ultrasound, diastematomyelia, 517 phenylalanine, PKU, 266 cides, 65 uterus phenylketonuria, phenylalanine, 266 dimorphism, DES, o,p'-DDT, rats, 363 methoxychlor, 437 phenytoin SFRs, industrial wastes, 31 vaginal surfaces, 427 human studies, 279, 281, 301 Silent Spring, Recurring, [br] 274 validation studies, 265, 267 morphogenic abnormalities, 281 sister chromatid exchange, ethanol, 405 valproate, membrane lipid synthesis, 255 phosphodiesterase inhibition, 473 sodium fluoride, rat, 505 vanadium, liver/testicular effects, rat, 513 phospholipids, membrane synthesis, 245 sperm vasal injection, sodium fluoride, rat, 505 pituitary chromatin structure assay, 115 videomicrography, rat sperm motility, 387 genistein, 127 methodologic issues, rat, 449 vinblastine, granulosa-luteal cells, in vitro, naturally occurring estrogens, 133 motility, rat, computer-assisted motion 371 responsiveness to GnRH, DES, rats, 363 analysis, 387 vinylcyclohexene diepoxide, ovarian toxic- PIXE, lead, mouse blastocyst, 53 motion, 39 ity, 379 PKU, phenylalanine, 266 transport, 347 vinylcyclohexene, 4-, ovarian toxicity, 379 postimplantation embryo culture, 223, 417 velocity, 449 visceral yolk sac pregnancy, amantadine, 65 standard fertility rates, 31 depentylase activities, 473 preimplantation period, ethanol, 405 Statistics cytochrome P450 isoforms, 259 progesterone rat sperm motility, 387 challenge, LH levels, 133 WEC, 237 whole embryo culture genistein, 127 stem cells, embryonic, 57 artifacts, 237 receptor, chlorinated pesticides, 65 structure-activity relationships, WEC, 255 chemicals, classification, 267 release, vinblastine, 371 student, graduate/postdoctoral awards, 531 comparison, two rat strains, 268 Proposition 65, California, 169, 175 styrene, occupational exposure, 3 phenylalanine, PKU protein substance abuse, prenatal, 87 postimplantation, 221 secretions, methoxychlor, 437 Teratogen Information Services, 463 retinoic acid, 266 uptake, WEC, 229 International Conference, 167 substituted phenols, 255 teratogenicity Witnessing, Expert, Effective, [br] 521 radiation, toxicity, fecundity, 385 screening in vitro, 57 x-ray microanalyses, particle-induced, 53 rat embryo, EGdiME, 157 EGdiME, 157 rat serum, 223 valproic acid, folate, 465 yolk sac reactive intermediates, WEC, 259 teratogens, epilepsy tissue, metabolic activity 267 Recurring Silent Spring, [br] 274 animal models, 279, 281 facial development, differential, 265 reductase, 5-alpha-, human studies, 301 WEC, 229 finasteride, 353 testicular inhibitor, male rats, 337 chromium, ultracellular changes, 443 zearalenone, 133